证券代码：000813 证券简称：德展健康 公告编号：2022-033 德展大健康股份有限公司 关于参加 2022 年新疆辖区投资者网上集体接待日活动的公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、 误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）为便于广大投资者更深入全 面地了解公司情况、发展战略、经营状况、融资计划、股权激励、可持续发展等 投资者所关心的问题，公司定于 2022 年 6 月 24 日参加由新疆上市公司协会联合 深圳市全景网络有限公司组织开展的 2022 年新疆辖区上市公司投资者网上集体 接待日活动。现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 络远程的方式举行，投资者可以登录全景网"投资者关系互动平台"网站 （http://ir.p5w.net/）或关注微信公众号：全景财经（微信号：p5w2012），参与 公司本次投资者集体接待日活动，活动时间为 2022 年 6 月 24 日下午（星期五）。 出席本次集体接待日的人员有：公司联席董事长兼总经理刘伟、副总经理兼 财务总监张婧红、董事会秘书周建 ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥192,816,625.91, a decrease of 8.87% compared to ¥211,589,350.75 in the same period last year[5]. - Net profit attributable to shareholders was ¥30,445,095.31, down 52.56% from ¥64,181,873.34 year-on-year[5]. - The company reported a net profit of ¥22,929,114.75 for the period, down 60.46% from ¥57,996,391.95 in the previous year[11]. - Basic and diluted earnings per share were both ¥0.0136, reflecting a decline of 52.61% from ¥0.0287 in the same period last year[5]. - Total operating revenue for the first quarter was ¥192,816,625.91, a decrease of 8.9% compared to ¥211,589,350.75 in the previous year[27]. - Net profit for the period was ¥22,929,114.75, down 60.5% from ¥57,996,391.95 in the same period last year[30]. - The total comprehensive income attributable to shareholders of the parent company was ¥30,445,095.31, down from ¥64,181,873.34 in the previous year[32]. Cash Flow - The net cash flow from operating activities decreased by 15.33%, amounting to ¥130,435,562.96 compared to ¥154,051,928.33 in the previous year[5]. - The cash inflow from operating activities totaled $299,649,594.13, a decrease of 29.4% compared to $423,978,066.95 in the previous period[34]. - The cash outflow from operating activities was $169,214,031.17, down 37.4% from $269,926,138.62 in the prior period[37]. - The net cash flow from operating activities was $130,435,562.96, a decline of 15.3% compared to $154,051,928.33 in the previous period[37]. - Cash inflow from investment activities was $80,551,396.03, significantly lower than $196,122,174.13 in the prior period, representing a decrease of 59.0%[37]. - The net cash flow from investment activities was -$15,445,078.29, compared to -$186,375,668.19 in the previous period, indicating an improvement[37]. - The company received $80,000,000.00 from the recovery of investments, down from $186,390,596.64 in the prior period, a decrease of 57.0%[37]. - The total cash outflow for investment activities was $95,996,474.32, down 75.1% from $382,497,842.32 in the previous period[37]. - The company reported a cash inflow of $98,881,175.84 from other operating activities, a significant increase from $13,111,086.01 in the previous period[34]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,854,779,624.68, an increase of 1.33% from ¥5,778,043,347.05 at the end of the previous year[5]. - The total assets of the company at the end of the reporting period amount to 5,854,779,624.68 yuan, an increase from 5,778,043,347.05 yuan at the beginning of the year[20]. - The company's cash and cash equivalents stand at 1,592,533,545.20 yuan, up from 1,473,720,797.44 yuan at the beginning of the year[20]. - The company's total current assets are reported at 4,056,672,615.21 yuan, compared to 3,562,755,881.68 yuan at the start of the year, indicating a growth of approximately 13.87%[20]. - The company has reduced its inventory from 300,017,175.21 yuan to 270,122,398.21 yuan, reflecting a decrease of about 9.93%[20]. - The company has a total of 457,366,466.97 yuan in long-term equity investments, slightly down from 459,617,483.71 yuan at the beginning of the year[20]. - The company’s total non-current assets decreased from 2,215,287,465.37 yuan to 1,798,107,009.47 yuan, a decline of approximately 18.75%[20]. - Total liabilities increased to ¥361,822,032.91, up from ¥308,053,292.52 year-over-year[26]. - Total equity attributable to shareholders of the parent company was ¥5,402,595,666.16, slightly up from ¥5,372,112,148.36[26]. Research and Development - The company's R&D expenses for Q1 2022 were ¥10,715,438.38, a decrease of 43.00% compared to ¥18,800,084.65 in the same period last year[8]. - Research and development expenses for the quarter were ¥10,715,438.38, down from ¥18,800,084.65 in the previous year[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 50,534, with the top ten shareholders holding significant stakes[12]. - Meilin Holdings Group holds 20.08% of shares, amounting to 448,263,156 shares, while Shanghai Yueye Equity Investment Management Partnership holds 18.55% with 414,138,066 shares[12]. Other Information - The company recorded a total of ¥1,092,360.73 in non-recurring gains and losses for the period[7]. - The company completed the repurchase and cancellation of 6,693,668 restricted shares, accounting for 0.30% of the total share capital before the repurchase[16]. - The company reported a financial asset impairment loss of ¥10,691,394.68 during the quarter[30]. - The company did not conduct an audit for the first quarter report[40].

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-on-year increase of 15%[23]. - The net profit attributable to shareholders was 150 million RMB, an increase of 20% compared to the previous year[23]. - The company's operating revenue for 2021 was ¥734,479,885.95, a decrease of 23.72% compared to ¥962,867,939.86 in 2020[33]. - The net profit attributable to shareholders for 2021 was -¥57,581,886.98, representing a decline of 120.24% from ¥284,544,408.49 in 2020[33]. - The net cash flow from operating activities for 2021 was ¥42,409,946.65, a significant drop of 94.88% from ¥827,536,288.77 in 2020[33]. - The total assets at the end of 2021 were ¥5,778,043,347.05, a decrease of 9.71% from ¥6,399,443,473.17 at the end of 2020[33]. - The net assets attributable to shareholders at the end of 2021 were ¥5,372,112,148.36, down 8.91% from ¥5,897,405,033.41 at the end of 2020[33]. - The basic earnings per share for 2021 was -¥0.0257, compared to ¥0.1282 in 2020, reflecting a decline of 120.05%[33]. - The company reported a total of ¥42,740,399.94 in non-recurring gains for 2021, compared to ¥87,627,947.45 in 2020[39]. - The company achieved a revenue of 734.48 million yuan in the reporting period, a decrease of 23.72% compared to the same period last year[59]. - The pharmaceutical sector accounted for 95.74% of total revenue, generating ¥703.17 million, down 26.66% from ¥958.79 million in the previous year[68]. - The company reported a significant increase in industrial hemp sales, with revenue rising by 711.12% to approximately ¥24.19 million[68]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2023[23]. - Future guidance indicates a revenue target of 1.5 billion RMB for 2022, reflecting a growth rate of 25%[23]. - The company is actively pursuing new business layouts, including functional beverages and liver health products, to capture emerging market opportunities[49]. - The company is actively expanding its product pipeline, including new businesses in peptide cosmetics, food and beverages, and influenza vaccines[53]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB for potential deals[189]. - Market expansion plans include entering three new international markets by the end of 2022, aiming for a 5% market share in each[196]. Research and Development - The company has invested 100 million RMB in R&D for new technologies, focusing on health management solutions[23]. - The company invested over ¥67 million in R&D in 2021, representing a year-on-year increase of approximately 19.64%[62]. - The company has four specialized pharmaceutical R&D institutions and over 100 experienced researchers dedicated to technology innovation and new drug development[57]. - The company is collaborating with Tsinghua University on a targeted cancer drug project, which is currently in the animal model efficacy exploration stage[63]. - The company is working on the development of a new drug for thrombosis with clinical advantages over existing treatments, which is expected to guide future innovative drug development[85]. - The company aims to enhance its R&D investment and improve innovation mechanisms to enhance product competitiveness and expand product varieties[137]. - The company plans to accelerate the research and development of peptide products and expand the product categories of its cosmetics line to create differentiated competitive advantages[140]. Operational Efficiency and Cost Management - The management emphasized the importance of enhancing operational efficiency, targeting a 5% reduction in costs over the next year[189]. - The company aims to reduce operational costs by 8% through various efficiency initiatives[196]. - The company has implemented a unified pricing policy to stabilize market operations and ensure fair competition in the retail pharmaceutical market[64]. - The company emphasizes the importance of managing production costs amid rising raw material prices and logistics costs by selecting quality suppliers and innovating production technologies[141]. Governance and Shareholder Relations - The company has established a comprehensive governance structure, ensuring compliance with legal and regulatory requirements, and promoting fair treatment of all shareholders[150]. - The company actively engages in investor relations activities, providing updates on new drug developments and market strategies to institutional investors[145]. - The company maintains complete independence from its controlling shareholder, Kaidi Investment, in terms of business, personnel, assets, organization, and finance[151]. - The company has a clear ownership structure with distinct asset ownership from the controlling shareholder, ensuring operational integrity[153]. - The annual general meeting held on May 21, 2021, had a participation rate of 59.37% and approved multiple resolutions including the 2020 financial report and profit distribution plan[154]. Challenges and Risks - The company has identified key risks in its future development strategy, including regulatory changes and market competition, and has outlined corresponding mitigation measures[6]. - The pharmaceutical industry is expected to face continued challenges in 2022, including price reductions and market competition, necessitating a focus on R&D innovation and marketing capabilities[136]. - The company acknowledges risks associated with new business ventures, particularly in the industrial hemp sector, which may be affected by macroeconomic fluctuations and policy changes[142]. - The company faces market and policy risks due to ongoing pharmaceutical policy reforms, which may significantly alter the market landscape and increase regulatory scrutiny[141].

Financial Performance - The company's revenue for Q3 2021 was ¥121,049,085.68, a decrease of 2.50% compared to the same period last year, and a year-to-date revenue of ¥512,869,188.98, down 38.85% year-on-year[4] - The net profit attributable to shareholders for Q3 2021 was ¥21,887,036.90, a decline of 61.58%, with a year-to-date net profit of ¥124,478,367.92, down 48.00% compared to the previous year[4] - The basic earnings per share for Q3 2021 was ¥0.0098, a decrease of 61.87%, with a year-to-date figure of ¥0.0556, down 48.47% year-on-year[4] - Total operating revenue for the current period is ¥512,869,188.98, a decrease of 38.7% compared to ¥838,759,369.84 in the previous period[30] - Net profit for the current period is ¥104,859,677.44, a decline of 55.0% from ¥233,504,193.20 in the previous period[33] - Earnings per share for the current period is ¥0.1079, compared to ¥0.1079 in the previous period[36] Assets and Liabilities - The company's total assets as of the end of Q3 2021 were ¥6,081,080,656.33, representing a decrease of 4.97% from the end of the previous year[4] - The company's current assets totaled CNY 3,569,312,979.07, down from CNY 4,799,418,955.30 at the end of 2020, indicating a decrease of about 25.66%[23] - Cash and cash equivalents decreased significantly from CNY 2,413,450,777.20 in December 2020 to CNY 1,234,238,991.95 by September 2021, a reduction of approximately 48.92%[20] - The total liabilities decreased from CNY 446,366,740.11 to CNY 411,964,759.52, a decline of approximately 7.68%[26] - Total liabilities amounted to 446,366,740.11, a decrease of 13,218,555.39 compared to the previous period[50] - Non-current liabilities totaled 33,339,286.91, reflecting a decrease from 40,794,194.80[50] Shareholder Information - The total number of common shareholders at the end of the reporting period is 47,246[11] - Meilin Holdings Group Limited holds 20.00% of shares, totaling 448,263,156 shares[11] - Shanghai Yueye Equity Investment Management Partnership holds 18.48% of shares, totaling 414,138,066 shares[11] - Xinjiang Kaidi Investment Limited Liability Company holds 18.28% of shares, totaling 409,748,445 shares[11] - The top ten shareholders collectively hold a significant portion of the company's shares, with the first three shareholders alone accounting for over 56%[11] - The company has a total of 0 preferred shareholders at the end of the reporting period[15] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥125,866,421.66, a significant decrease of 84.21% compared to the previous year[10] - Cash flow from operating activities is ¥741,567,155.95, significantly lower than ¥1,479,836,397.22 in the previous period[37] - Cash outflow from investing activities totaled $882.09 million, down from $2.45 billion, resulting in a net cash flow from investing activities of -$239.30 million[40] - Cash flow from financing activities showed a net outflow of -$473.24 million, compared to a net inflow of $27.69 million in the previous period[40] Expenses - Research and development expenses for the year-to-date period increased by 47.87% to ¥51,929,287.83, reflecting increased investment in R&D projects[10] - The company reported a decrease in sales expenses by 43.21% to ¥109,966,938.92, attributed to reduced product promotion costs[10] - The company reported a decrease in sales expenses to ¥109,966,938.92 from ¥193,651,609.36, reflecting cost-cutting measures[30] Strategic Changes - The company is undergoing a transition in its board of directors, with new appointments expected to influence future strategic directions[4] - The company has temporarily suspended cooperation on investment matters due to changes in its controlling shareholder, pending the establishment of a new board[4] - The company is focusing on expanding its market presence and exploring new investment opportunities in the carbon asset sector[4] Other Financial Metrics - The company's non-current assets increased to CNY 2,511,767,677.26 from CNY 1,600,024,517.87, representing a growth of about 56.88%[23] - The company has a minority interest loss of ¥19,618,690.48, compared to a loss of ¥5,895,417.17 in the previous period[33] - The company has not audited its third-quarter report[50] - The retained earnings were reported at 4,420,938,435.31, unchanged from the previous period[50]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥391,820,103.30, a decrease of 45.17% compared to ¥714,601,279.87 in the same period last year[29]. - The net profit attributable to shareholders for the first half of 2021 was ¥102,591,331.02, down 43.77% from ¥182,437,104.68 in the previous year[29]. - The net cash flow from operating activities was ¥156,926,755.49, representing a significant decline of 79.18% compared to ¥753,682,581.12 in the same period last year[29]. - Basic earnings per share for the first half of 2021 were ¥0.0458, a decrease of 44.35% from ¥0.0823 in the previous year[29]. - Total assets at the end of the reporting period were ¥6,065,391,673.74, down 5.22% from ¥6,399,443,473.17 at the end of the previous year[29]. - The net assets attributable to shareholders decreased by 6.21%, from ¥5,897,405,033.41 to ¥5,531,147,661.76[29]. - The weighted average return on net assets was 1.75%, down 1.45% from 3.20% in the previous year[29]. - The net profit after deducting non-recurring gains and losses was ¥91,322,843.55, a decrease of 43.68% from ¥162,161,936.88 in the same period last year[29]. - The company achieved operating revenue of 391.82 million yuan, a decrease of 45.17% compared to the same period last year[47]. - The net profit attributable to shareholders was 102.59 million yuan, down 43.77% year-on-year[47]. - The total assets amounted to 6.07 billion yuan, a decline of 7.72% from the previous year[47]. - The cost of goods sold was ¥123,323,997.59, down 31.17% from ¥179,176,289.08, primarily due to reduced sales volume[55]. - Research and development expenses increased by 55.71% to ¥33,910,813.92 from ¥21,778,542.84, reflecting increased investment in R&D projects[55]. - The gross profit margin for the pharmaceutical sector was 68.64%, down 6.92% from the previous year[59]. - The sales revenue from pharmaceutical products was ¥377,605,541.89, representing 96.37% of total revenue, with a year-on-year decrease of 45.91%[58]. Business Strategy and Development - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company has highlighted potential risks and countermeasures in its future development strategy[6]. - The core drug "Alet" (Atorvastatin Calcium Tablets) is positioned as a market leader, being the first in China to pass the consistency evaluation for this product[39]. - The company has obtained registration certificates for two specifications of Amlodipine Atorvastatin Calcium Tablets and is actively promoting their production and sales[39]. - The company is diversifying into new business areas, including biopolypeptides, food and beverages, and cosmetics, while also being the exclusive agent for Taiwan's Guoguang flu vaccine in mainland China[39]. - The company’s marketing strategy for its pharmaceutical business includes a distributor and promoter model, focusing on "sales-driven production"[40]. - The company aims to enhance brand recognition and product awareness through various promotional activities, including seasonal promotions and participation in industry exhibitions[41]. - The company is focusing on expanding its OTC market presence and enhancing product promotion in retail pharmacies[41]. - The company is actively expanding its product pipeline, including new flavors and packaging for the "Xiao Lan" beverage series expected to launch in Q3[48]. - The company is collaborating with a subsidiary on a DNA therapeutic drug project, which has shown positive results in a Phase III clinical trial[161]. - The company is actively pursuing market expansion and new product development strategies[164]. Risks and Challenges - The company faces market and policy risks due to ongoing pharmaceutical policy reforms and increasing regulatory scrutiny, which may impact operations[78]. - The company plans to enhance R&D investment and innovate drug development to mitigate risks associated with drug procurement policies and market competition[78]. - The company faces increased risks in quality control due to stricter regulations on drug development and marketing, necessitating robust internal controls to ensure drug safety[81]. - Rising production costs are anticipated due to increases in raw material prices, logistics costs, and labor, prompting the company to implement a qualified supplier management system and innovate production technologies to control costs[81]. - New business ventures, particularly in food and beverage and peptide cosmetics, face risks from macroeconomic fluctuations, potential policy changes, and intensified market competition[81]. - The company plans to adhere strictly to national laws and regulations regarding new business collaborations, particularly in the industrial hemp sector, to mitigate associated risks[82]. Environmental Compliance - Environmental compliance is maintained, with no exceedances reported in pollutant emissions across various categories[96]. - The company has implemented a wastewater treatment facility that is operating normally, ensuring compliance with environmental standards[106]. - The company has upgraded its boiler to low-nitrogen specifications, reducing pollutant emissions[106]. - The wastewater treatment plant's effluent quality, including pH, suspended solids, BOD, COD, total nitrogen, ammonia nitrogen, and total phosphorus, meets environmental discharge standards[106]. - The company has set up a hazardous waste storage facility, ensuring proper classification and storage of hazardous materials[106]. - The company has conducted VOC modification projects in its solid preparation workshop, ensuring compliance with emission standards[106]. - The company has developed an emergency response plan for environmental incidents, which includes regular drills to ensure preparedness[112]. - The company has established a comprehensive self-monitoring plan for emissions, ensuring regular data recording and compliance with environmental standards[111]. Shareholder and Corporate Governance - The annual shareholders' meeting had a participation rate of 59.37%, where key resolutions including the profit distribution plan and adjustments to fundraising projects were approved[86]. - The company has implemented an employee stock ownership plan, with a total of 2,665,113 shares subscribed at a price of 9.93 yuan per share, amounting to 26.4646 million yuan[90]. - The first phase of the company's stock incentive plan was approved, granting a total of 21,612,228 restricted shares at a price of 1.85 yuan per share[91]. - The company has not distributed cash dividends or bonus shares for the half-year period[87]. - The company reported a total share capital of 2,241,481,800 shares, with 99.04% being unrestricted shares[170]. - The company’s financial statements for 2020 received a qualified opinion from the auditing firm, indicating potential issues[165]. - The board of directors is addressing the audit firm's qualified opinion by communicating with trust institutions to mitigate risks, with a total of 20 million yuan in principal and corresponding investment income already redeemed as of June 30, 2021[127]. - The company has no significant litigation or arbitration matters during the reporting period[129]. - There are no major related party transactions reported during the period[130]. - The company has engaged in entrusted financial management with a total amount of 70 million yuan, including 18 million yuan in bank financial products and 42 million yuan in trust financial products[144]. - The overdue amount from entrusted financial management is 738.65 thousand yuan, which has been fully provisioned for impairment[144]. - The company has no major guarantees during the reporting period[143]. - The company has not experienced any bankruptcy reorganization matters during the reporting period[128]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[186]. - The company has no preferred shares in existence during the reporting period[190].

证券代码：000813 证券简称：德展健康 公告编号：2021-032 德展大健康股份有限公司 关于参加 2021 年新疆辖区 投资者网上集体接待日活动的公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）为便于广大投资者更深入全 面地了解公司情况、发展战略、经营状况、融资计划、股权激励、可持续发展等 投资者所关心的问题，公司定于 2021 年 6 月 18 日参加由新疆上市公司协会联合 深圳市全景网络有限公司组织开展的 2021 年新疆辖区上市公司投资者网上集体 接待日活动。现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 络远程的方式举行，投资者可以登录全景网"投资者关系互动平台"网站 （http://ir.p5w.net/）或关注微信公众号：全景财经（微信号：p5w2012），参 与公司本次投资者集体接待日活动，活动时间为 2021 年 6 月 18 日（星期五）。 出席本次集体接待日的人员有：总经理刘伟、董事会秘书杜业松、财务总监 张婧红。 欢迎广大投资者积极参与。 ...

Financial Performance - The company reported a total revenue of 2,239,481,800 RMB for the year 2020, with a cash dividend of 2.1 RMB per 10 shares distributed to all shareholders[6]. - The company's operating revenue for 2020 was ¥962,867,939.86, a decrease of 45.75% compared to ¥1,774,968,109.63 in 2019[26]. - The net profit attributable to shareholders for 2020 was ¥284,544,408.49, down 15.55% from ¥336,921,030.17 in 2019[26]. - The net profit after deducting non-recurring gains and losses for 2020 was ¥196,916,461.04, a decrease of 22.83% compared to ¥255,176,480.19 in 2019[26]. - The net cash flow from operating activities for 2020 was ¥827,536,288.77, a decline of 46.91% from ¥1,558,808,735.93 in 2019[29]. - The basic earnings per share for 2020 was ¥0.1282, down 15.60% from ¥0.1519 in 2019[29]. - The total profit for 2020 was CNY 349.26 million, down 9.93% year-on-year, while the net profit attributable to shareholders was CNY 284.54 million, a decline of 15.55%[54]. - The company reported a net profit of 1,283,791,531.79 yuan for the parent company in 2020, allowing for a distributable profit of 541,835,925.70 yuan after covering previous losses[145]. Assets and Investments - Total assets at the end of 2020 were ¥6,399,443,473.17, an increase of 7.96% from ¥5,927,795,521.33 at the end of 2019[29]. - The net assets attributable to shareholders at the end of 2020 were ¥5,897,405,033.41, up 5.07% from ¥5,612,860,624.92 at the end of 2019[29]. - The company’s long-term equity investments increased to ¥357,818,728.20, up 3.08% from ¥148,915,235.54 in 2019[95]. - The total investment amount for the reporting period was ¥1,026,000,000, representing a 62.16% increase compared to ¥632,689,610 in the same period last year[101]. Research and Development - The company has invested in R&D with over 100 specialized personnel across three research institutions, focusing on both generic and innovative drug development[46]. - R&D investment totaled ¥56,046,274.64, a decrease of 52.73% compared to ¥118,569,038.90 in 2019, representing 5.82% of operating revenue[87]. - The number of R&D personnel increased to 220, up 62.96% from 135 in 2019, with R&D personnel accounting for 19.43% of the total workforce[87]. - The company is committed to increasing R&D investment, with plans to complete 3 new product projects and apply for at least 3 invention patents in 2021[132]. Market Strategy and Expansion - The company plans to expand its market presence and enhance its product offerings, focusing on new product development and technological advancements[6]. - The company has diversified into new business areas such as biopolypeptide products, industrial hemp food and beverages, and industrial hemp cosmetics, indicating a strategic expansion beyond its core pharmaceutical operations[41]. - The company aims to expand its retail market coverage and brand building, focusing on increasing the number of retail terminals to replace hospital sales channels[128]. - The company is actively pursuing mergers and acquisitions to enrich its product pipeline in oncology, rare diseases, and fast-moving consumer goods sectors[128]. Risk Management - The company has acknowledged potential risks in its future development and has outlined corresponding risk management strategies[6]. - The company anticipates ongoing challenges from market and policy risks due to deepening medical reforms and stricter regulations[136]. - The company has faced increased risks in quality control due to new regulations and standards in the pharmaceutical industry[137]. Corporate Governance and Compliance - The company has established strict internal controls and management systems to ensure drug quality safety in compliance with national regulations[137]. - The company is cautious about new business ventures, particularly in industrial hemp and disinfectant products, due to potential macroeconomic fluctuations and policy changes[138]. - The company has committed to not providing financial assistance for the equity incentive plan, ensuring compliance with relevant regulations[174]. Acquisitions and Restructuring - The company successfully acquired 65.00% of Hantai Biological for a cost of ¥266.5 million, gaining control on April 30, 2020[182]. - The company also acquired 67.01% of Hancui Tianjin for ¥19.5 million, also on April 30, 2020[182]. - The acquisition of Shouhui Pharmaceutical was completed on January 31, 2020, for ¥33 million, resulting in a 51.00% ownership[182]. - The company has committed to ensuring the independence of its operations and avoiding unnecessary related party transactions[154]. Production and Quality Control - The company has established a robust marketing channel through a network of quality agents, enhancing its competitive advantage in the market[46]. - The company has received multiple accolades, including being ranked 65th in the "Top 100 Chinese Chemical Pharmaceutical Enterprises" and recognized for its social contributions and integrity[42]. - The company has conducted a thorough evaluation of project feasibility, leading to the decision to halt further construction of the second phase of the Jialin Pharmaceutical project[116].

Financial Performance - The company's operating revenue for Q1 2021 was ¥211,589,350.75, a decrease of 55.01% compared to ¥470,318,621.70 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥64,181,873.34, down 29.90% from ¥91,561,632.00 in the previous year[8]. - The net profit after deducting non-recurring gains and losses was ¥61,151,767.07, a decrease of 16.26% compared to ¥73,029,190.26 in the same period last year[8]. - Basic and diluted earnings per share for Q1 2021 were both ¥0.0287, a decrease of 30.51% from ¥0.0413 in the same period last year[8]. - Operating revenue decreased by 55.01% to ¥211.59 million, attributed to a decline in sales volume and selling price[20]. - Operating costs decreased by 48.21% to ¥64.15 million, mainly due to reduced sales volume[20]. - The company reported a significant increase in other payables, which rose to ¥361,794,769.19 from ¥295,209,596.61, a growth of approximately 22.5%[58]. - Total operating revenue for the current period is CNY 211,589,350.75, a significant decrease from CNY 470,318,621.70 in the previous period, representing a decline of approximately 55%[70]. - Net profit for the current period is CNY 57,996,391.95, compared to CNY 91,064,829.49 in the previous period, reflecting a decrease of approximately 36%[76]. - The total profit for the current period is CNY 70,774,219.94, compared to CNY 124,292,406.84 in the previous period, indicating a decline of about 43%[76]. Cash Flow - The net cash flow from operating activities was ¥154,051,928.33, down 66.20% from ¥455,715,435.22 in the previous year[8]. - Cash flow from operating activities was 154,051,928.33, significantly lower than 455,715,435.22 in the previous period, reflecting a decrease in cash generation[92]. - The company received cash of 410,866,105.80 from sales of goods and services, down from 679,122,808.80 in the previous period[88]. - Cash inflow from investment activities was 196,122,174.13, compared to 852,448,187.27 in the previous period, showing a substantial decline[92]. - Cash outflow from investment activities totaled 382,497,842.32, down from 1,800,786,324.78 in the previous period, indicating reduced investment spending[92]. - The ending cash and cash equivalents balance was 1,779,307,354.72, compared to 981,721,408.66 in the previous period, showing an increase in liquidity[94]. - The company paid 45,996,313.30 for goods and services, compared to 7,807,303.10 in the previous period, indicating increased operational costs[92]. - Cash inflow from investment activities totaled $238.10 million, a significant increase from $30.13 million in the previous period[98]. - Cash outflow from investment activities was $308.42 million, compared to $827.55 million last year, resulting in a net cash flow from investment activities of -$70.31 million[98]. - The net increase in cash and cash equivalents was -$57.80 million, compared to -$783.68 million in the previous period[98]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,466,510,166.45, an increase of 1.05% from ¥6,399,443,473.17 at the end of the previous year[8]. - Current liabilities rose to ¥422,914,640.32 from ¥413,027,453.20, representing an increase of approximately 2.14%[58]. - Total liabilities amounted to ¥455,413,057.28, compared to ¥446,366,740.11, showing a growth of around 2.34%[58]. - The company's total liabilities amount to CNY 1,900,781,079.04, slightly up from CNY 1,839,629,493.35 in the previous period, showing an increase of about 3%[68]. - Total equity stands at CNY 11,004,429,346.89, a minor decrease from CNY 11,023,162,063.91 in the previous period, representing a decline of approximately 0.17%[68]. Investments and R&D - The company increased its investment in Beijing Dongfang Lue Bio-pharmaceutical Technology Co., Ltd., raising its stake to 23.22%[23]. - The company announced positive results from a Phase III clinical trial for a DNA therapeutic drug in collaboration with Inovio Pharmaceuticals[23]. - The R&D project for cardiovascular and tumor treatment drugs is facing increased difficulty due to changes in national drug review policies[35]. - Research and development expenses for the current period are CNY 18,800,084.65, an increase from CNY 15,569,693.37 in the previous period, indicating a growth of about 20%[73]. Shareholder Information - The top shareholder, Meilin Holdings Group, holds 24.44% of the shares, with a total of 547,744,307 shares[13]. - The total number of ordinary shareholders at the end of the reporting period was 49,903[13]. Miscellaneous - The company has not engaged in derivative investments during the reporting period[28]. - The company has not reported any overdue commitments from actual controllers, shareholders, or related parties during the reporting period[26]. - The company has not engaged in any research, communication, or interview activities during the reporting period[48]. - The company has not reported any significant contracts or non-operating fund occupation by controlling shareholders during the reporting period[46][47].

Financial Performance - Operating revenue for the reporting period was ¥124,158,089.97, a decrease of 74.27% year-on-year[9]. - Net profit attributable to shareholders was ¥56,962,505.69, down 40.85% compared to the same period last year[9]. - Basic earnings per share were ¥0.0257, reflecting a decrease of 40.78% compared to the same period last year[9]. - The weighted average return on net assets was 0.98%, down 0.75% from the previous year[9]. - Revenue for the first nine months of 2020 was approximately ¥838.8 million, a decrease of 40.28% compared to ¥1.4 billion in the same period of 2019, primarily due to the impact of volume-based procurement policies[26]. - Net profit for the first nine months of 2020 was approximately ¥233.5 million, down 30.85% from ¥337.7 million in the previous year, influenced by reduced operating income[26]. - The total operating profit for the period was 73,306,787.14, a decrease from 112,464,190.80 in the previous period[88]. - The net profit for the period was 53,983,283.17, down from 95,754,034.85 in the previous period, representing a decline of approximately 43.8%[88]. - The total profit for the period was 74,118,687.68, compared to 112,470,165.64 in the previous period, indicating a decrease of about 34%[88]. - The total comprehensive income attributable to the parent company was 56,962,505.69, down from 96,299,299.51 in the previous period[91]. Cash Flow - The net cash flow from operating activities was ¥43,537,008.95, a significant decline of 93.35% year-on-year[9]. - The cash flow from operating activities for the first nine months of 2020 was approximately ¥797.2 million, a decrease of 44.37% from ¥1.4 billion in the previous year[26]. - Cash inflow from operating activities totaled 1,479,836,397.22 CNY, down from 2,790,451,465.21 CNY year-over-year, reflecting a decrease of approximately 47%[115]. - The net cash flow from operating activities was 797,219,590.07 CNY, compared to 1,433,007,121.50 CNY in the previous period, showing a decline of about 44%[115]. - The net cash flow from investment activities was -869,122,869.10 CNY, compared to -2,106,848,351.10 CNY in the previous period, showing an improvement[118]. - The net cash flow from financing activities was 27,685,144.27 CNY, compared to -5,546,260.58 CNY in the previous period, indicating a positive shift[118]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,632,937,948.19, an increase of 11.90% compared to the end of the previous year[9]. - Total liabilities amounted to ¥794,738,645.08, a significant increase from ¥316,152,923.63[72]. - Total equity attributable to shareholders reached ¥5,709,183,447.51, up from ¥5,612,860,624.92[75]. - The company's total liabilities included short-term borrowings of CNY 19 million as of September 30, 2020[69]. - The company's cash and cash equivalents decreased to approximately CNY 1.43 billion from CNY 1.48 billion year-over-year[66]. - The company's trading financial assets decreased to approximately CNY 1.98 billion from CNY 2.09 billion year-over-year[66]. - The company has a non-current asset total of approximately CNY 2.30 billion, up from CNY 916.55 million at the end of 2019[69]. - Total liabilities for the current period were ¥2,296,740,414.30, compared to ¥1,448,500,106.11 previously[81]. Shareholder Information - The company reported a total of 35,833 shareholders at the end of the reporting period[13]. - The largest shareholder, Meilin Holdings Group, held 24.44% of the shares[13]. - The company’s controlling shareholder, Meilin Holdings, has undergone changes in shareholding, with significant transfers noted[36]. Investment and Development - The company completed the acquisition of a subsidiary, resulting in goodwill increasing by 3579.52% to approximately ¥850.5 million[23]. - The company plans to expand its market presence and enhance product offerings through strategic acquisitions and investments in new technologies[27]. - The company is diversifying its business focus from generic drugs to innovative drugs and other health-related fields due to significant changes in the pharmaceutical industry environment[54]. - The company is currently evaluating the feasibility of its drug development projects due to changes in national drug review policies and industry dynamics[49]. Research and Development - Research and development expenses decreased by 61.00% to approximately ¥35.1 million, reflecting reduced investment in R&D projects[26]. - Research and development expenses for the period were 13,340,339.13, down from 40,305,097.53 in the previous period, reflecting a reduction of approximately 66.9%[88]. - Research and development expenses for the current period are ¥35,118,881.97, significantly lower than ¥90,050,914.59 in the previous period[99]. Government Support and Subsidies - The company received government subsidies amounting to ¥4,467,423.04 during the reporting period[11]. Compliance and Governance - The company has not reported any share buyback activities during the reporting period[36]. - The company has not engaged in any securities or derivative investments during the reporting period[38][39]. - The company reported no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[36]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[61].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2020, representing a year-on-year increase of 15%[19] - The net profit attributable to shareholders was RMB 200 million, up 10% compared to the same period last year[19] - Future guidance indicates a projected revenue growth of 20% for the full year 2020[19] - The company's operating revenue for the reporting period was ¥714,601,279.87, a decrease of 22.48% compared to the same period last year[26] - The net profit attributable to shareholders was ¥182,437,104.68, down 24.59% year-on-year[26] - The net profit after deducting non-recurring gains and losses was ¥162,161,936.88, reflecting a decline of 29.69% compared to the previous year[26] - The net cash flow from operating activities was ¥753,682,581.12, a decrease of 3.20% from the same period last year[26] - Total assets at the end of the reporting period reached ¥6,572,873,929.72, an increase of 10.88% compared to the end of the previous year[26] - The net assets attributable to shareholders amounted to ¥5,795,297,729.60, up 3.25% from the previous year[26] Market Expansion and Strategy - User data showed an increase in active users by 25%, reaching 5 million by the end of June 2020[19] - The company plans to expand its market presence in Southeast Asia, targeting a 30% growth in that region by the end of 2021[19] - Strategic partnerships are being formed to enhance supply chain efficiency, aiming for a 15% reduction in operational costs[19] - The company is exploring potential acquisitions to diversify its product offerings and expand its market share[19] - The company is actively expanding into the OTC market to recover profits and strengthen hospital market promotion[36] - The company is actively promoting new business layouts, including the launch of industrial hemp beverages and ongoing drug research for CBD treatment[53] Research and Development - The company has invested RMB 100 million in R&D for new technologies, focusing on health management solutions[19] - New product launches are expected to contribute an additional RMB 300 million in revenue for the second half of 2020[19] - The company has four new drug projects under research and numerous category three new drugs in development[49] - The company has made significant investments in R&D, including relocating its subsidiary and upgrading laboratory equipment[49] - The company is advancing the development of NMN health products aimed at delaying aging and improving vitality[49] Product Performance - The main product "Aler" has maintained a stable user base and brand loyalty, contributing to its competitive advantage in the market[41] - The main product "Aler" achieved sales of 116 million boxes (calculated at 10mg) during the reporting period[49] - "Aler" ranked second in retail pharmacy sales of atorvastatin, accounting for approximately 11.09%, following Pfizer's Lipitor at 70.95%[49] - The production of "Aler" 10mg decreased by 13.1% compared to the previous year, while the production of "Aler" 20mg increased by 11.12% due to new production facilities[50] Compliance and Governance - The company will not distribute cash dividends or issue bonus shares for this fiscal year[7] - The company has ongoing commitments to avoid unnecessary related-party transactions, ensuring fair and transparent dealings to protect shareholder interests[90] - The company remains committed to avoiding direct or indirect competition with its subsidiaries, ensuring compliance with competitive regulations[94] - The company has not experienced any major litigation or arbitration matters during the reporting period[114] - The company has not faced any penalties or rectification issues during the reporting period[115] Risks and Challenges - The company is facing market and policy risks due to ongoing pharmaceutical policy reforms and stricter regulations[83] - The company plans to increase R&D investment and enhance product quality to maintain competitive advantages in response to pricing pressures from bulk purchasing policies[83] - The company faces significant risks in new drug research and development due to high funding requirements and long timelines, necessitating substantial annual investments[84] - Rising production costs due to increased raw material prices and logistics costs pose a risk, which the company aims to manage through supplier management and production technology innovations[84] - The company identifies risks in new business areas such as industrial hemp and disinfectant products, particularly related to macroeconomic fluctuations and policy changes[85] Shareholder Information - The company held two temporary shareholder meetings with participation rates of 47.43% and 63.14% respectively, indicating active investor engagement[89] - The company plans not to distribute cash dividends or issue bonus shares for the half-year period, focusing on capital retention[90] - The company has a total of 42,000,000 CNY in trust financial products, all sourced from self-owned funds[132] - The largest shareholder, Meilin Holdings Group, holds 28.20% of the shares, totaling 631,993,775 shares, with a decrease of 44,831,700 shares during the reporting period[161] - The total number of common shareholders at the end of the reporting period was 33,104[161] Financial Management - The total current assets as of June 30, 2020, amounted to CNY 4,397,055,842.51, a decrease of 12.24% from CNY 5,011,241,306.41 on December 31, 2019[193] - Cash and cash equivalents decreased to CNY 1,273,234,967.94 from CNY 1,481,706,244.07, representing a decline of 14.06%[193] - Total liabilities amounted to ¥645,581,121.99, compared to ¥316,152,923.63 previously, showing a growth trend[199] - Owner's equity remains stable at ¥945,609,943.00, indicating no changes in capital structure[199] - The company has accrued employee compensation liabilities of ¥3,547,671.19, which is part of its operational expenses[199]